We have associated pharmacological studies to a semi-quantitative evaluation of P-glycoprotein(s) expression, to establish if classical multidrug resistance (MDR) could account for the complete resistance phenotype exhibited by progressively doxorubicin-resistant rat glioblastoma cells. Three resistant variants (C6 0.001, C6 0.1 and C6 0.5) of the C6 glioblastoma cell line (C6 S) were selected by long-term culture in the presence of three concentrations of doxorubicin (0.001, 0.1 and 0.5 psg.ml-respectively). The degree of doxorubicin resistance was respectively 7, 33 and 400, and all the cell variants were cross-resistant to m-AMSA, etoposide and vincristine. Doxorubicin incorporation was reduced similarly in all resistant cells, irrespective of the level of resistance. When exposed to their respective doxorubicin IC50, the 7-fold resistant cells had the same intracellular drug incorporation as the sensitive cells, whereas the 33-fold and 400-fold resistant cells could incorporate respectively 3.7 and 17 times more drug. The ratio of doxorubicin exposures required for 50% DNA synthesis inhibition and 50% growth inhibition was dependent on the degree of resistance; this ratio was 12.8 in C6 S, 11.6 in C6 0.001, 6.3 Emergence of multidrug-resistant (MDR) tumour cells during treatment is one of the major problems in cancer chemotherapy. This resistance has been studied using drugresistant cell lines as an experimental model of this phenomenon. Multidrug resistance is characterised by crossresistance to functionally and structurally unrelated drugs (Skovsgaard, 1978) and by an impaired drug accumulation as compared to the sensitive parental cell lines (Dano, 1973) . Concommitantly, overexpression of a high molecular weight membrane glycoprotein (P-glycoprotein), encoded by the mdrl gene, is usually observed with the emergence of multidrug resistance (Juliano & Ling, 1976) . Decreased drug retention has been attributed mainly to enhanced active efflux of the drug out of the cells, which is thought to occur via Pglycoprotein (Gerlach et al., 1986 ) (see for review Bradley et al., 1989; Endicott & Ling, 1989).
Emergence of multidrug-resistant (MDR) tumour cells during treatment is one of the major problems in cancer chemotherapy. This resistance has been studied using drugresistant cell lines as an experimental model of this phenomenon. Multidrug resistance is characterised by crossresistance to functionally and structurally unrelated drugs (Skovsgaard, 1978) and by an impaired drug accumulation as compared to the sensitive parental cell lines (Dano, 1973) . Concommitantly, overexpression of a high molecular weight membrane glycoprotein (P-glycoprotein), encoded by the mdrl gene, is usually observed with the emergence of multidrug resistance (Juliano & Ling, 1976) . Decreased drug retention has been attributed mainly to enhanced active efflux of the drug out of the cells, which is thought to occur via Pglycoprotein (Gerlach et al., 1986 ) (see for review Bradley et al., 1989; Endicott & Ling, 1989) .
Multidrug-resistance can be reversed to various extents by treatment of cells with the calcium channel blocker verapamil (Tsuruo et al., 1981) . It is now clear that verapamil exerts its action by a mechanism that does not involve voltage-gated calcium channels (Huet & Robert, 1988) . However, the exact mechanism of this effect is still unknown. The circumvention of resistance is associated with increased drug accumulation, probably through interaction of verapamil with the outward drug transporter of resistant cells, P-glycoprotein. Data demonstrating that verapamil inhibits the vinblastine photoaffinity labelling of P-glycoprotein suggest that interaction of this agent with P-glycoprotein could be the biochemical basis for its pharmacological effects in MDR cells (Cornwell et al., 1986) . Moreover, using photoaffinity analogs of verapamil, Safa (1988) has shown that Pglycoprotein in MDR cells is a specific acceptor for verapamil.
The relationship between drug incorporation and cytotoxicity of anthracyclines has been extensively studied with different approaches. In glioblastoma cells with high level of resistance, we have shown that resistant cells can tolerate higher amounts of drug than sensitive cells for a similar cytotoxicity (Schott & Robert, 1989) . It had been also observed with this model that DNA synthesis inhibition occurred for higher doses than growth inhibition only in sensitive cells, suggesting that a distinct mechanism of cell death occurred in sensitive and resistant cells. Such features are not explained by the simple conception of P-glycoprotein as the unique mechanism for multidrug resistance, and suggest that additional mechanism(s) may lead to multidrug resistance.
Alternative forms of multidrug resistance became apparent in recent studies, especially a mechanism associated with alterations of DNA-topoisomerase II. This particular resistance was named by W.T. Beck 'atypical' MDR. In contrast to 'classical' P-glycoprotein-mediated MDR, cells expressing atypical MDR have no alteration in drug accumulation and retention, and do not overexpress P-glycoprotein (Beck et al., 1987; Morrow & Cowan, 1990 Then, the monolayers were washed twice with 0.15 M NaCl, harvested after gentle stirring and pelleted at 3,000 r.p.m. for 5 min. These steps were rapidly performed in order to avoid any efflux of the drug; 0.5 ml of water and 0.5 ml of 40% trichloracetic acid were successively added and the samples were kept at 4°C overnight, then centrifuged for 30 min at 3,000 r.p.m. The acid-soluble fraction was used to evaluate the intracellular concentration of non-covalently bound drug by fluorometry (spectrofluorometer SFM25 Kontron) with excitation and emission wavelengths set at 468 nm and 592 nm respectively. The acid-insoluble pellet was solubilised with 1 M NaOH and used to evaluate both the protein content (Lowry et al., 1951) (Figure 1 ). Intracellular level of doxorubicin required for 50% growth inhibition (GICm) in C6 0.001 was identical to that of sensitive cells (Table II) . In contrast, in C6 0.1 and C6 0.5 cells, doxorubicin levels exceeded those of the parent cell line, by 3.7 times and 17 times respectively.
It is worth noting that for 50% inhibition of DNA synthesis C6 sensitive cells and C6 0.001 cells had incorporated ten times more doxorubicin than for 50% growth inhibition, and that this value markedly decreased in C6 0.1 and C6 0.5 cells.
Doxorubicin retention Doxorubicin efflux was more important in resistant cells than in sensitive cells but was not dependent on the degree of resistance. Indeed, doxorubicin retention was identical in C6 0.1 cells and C6 0.5 cells, and only slightly higher in C6 0.001 cells during the first hour of efflux ( Figure 2 ). P-glycoprotein expression P-glycoprotein expression was quantified by Western blotting using the C219 monoclonal antibody, which recognises a very well-conserved epitope in the C-terminal part of P-glycoprotein. The P-glycoprotein detected in the sensitive line and the three resistant variants had the same apparent molecular weight of 135 kDa ( Figure  3a) . Resistant variants contained more P-glycoprotein than sensitive cells; this increase was proportional to resistance factor in C6 0.001 and C6 0.1 lines which contained respectively 10-25 and 50-75 times more P-glycoprotein than the sensitive line; it was no longer related to resistance factor in the C6 0.5 line which contained 75-100 times more Pglycoprotein than the sensitive line (Figure 3b ). (Table IV) Effect of verapamil on doxorubicin-induced DNA synthesis inhibition Verapamil effect on inhibition of 3H-thymidine incorporation in C6 sensitive and resistant variants is presented in Table III (Chang et al.,1989; Kessel & therefore likely that mechanism(s) other than doxorubicin efflux must be operating in the most resistant cells and the purpose of this work was to bring further evidence to this assumption.
In the C6 0.001 and C6 0.1 lines, the cross-resistance pattern was the one classically observed in multidrug resistant cells, with a slightly higher resistance to the selecting agent (doxorubicin) than to the other drugs; in the C6 0.5 line however, the resistance to doxorubicin further increases 12 times when compared to the C6 0.1 line, whereas resistance to the other agents was only twice higher. This is in agreement with the emergence in this line of supplementary doxorubicin-specific mechanism of resistance.
Another primary observation was the fact that DNA syna IV UV thesis inhibition was obtained for much higher doxorubicin (±M) exposures than growth inhibition in C6 S and C6 0.001 cells, whereas doxorubicin doses required for DNA synthesis orubicin incorporation in inhibition and growth inhibition were much closer in C6 0.5 were exposed for 2 h to cells, as already pointed out by us (Schott & Robert, 1989 GIC50 and TIC50 were defined in Table II . They were determined in the presence of various concentrations of verapamil, from 0.1 to 30 jAM.
Values are means of two or three independent experiments performed in triplicate. (1989) found a positive correlation between P-glycoprotein expression and the level of doxorubicin resistance; however, for resistance factors in the range 10-250, they observed that P-glycoprotein expression was not significantly different. Verapamil reversal of doxorubicin resistance and incorporation provided new insights on the questions raised. This drug had a dose-dependent effect up to 3 IM, but the effect of this modulator reaches then a plateau, beyond which no further reduction of GIC50 was obtained. Thus, it appears that 1 tiM of verapamil completely reversed multidrug resistance in C6 0.001, but partially reversed multidrug resistance in C6 0.1 and C6 0.5; the reversal remained partial even with the highest concentration of verapamil, which could however restore drug incorporation at the same level as in sensitive cells, and completely suppress doxorubicin efflux. Similar results had been observed with human ovarian cancer cells (Rogan et al., 1984) . It is worth to note that, in each cell line, DNA synthesis inhibition paralleled growth inhibition, so that the ratio TICjo/GICm was constant in each resistant variant, whatever the concentration of verapamil. This observation is in favour of a limitation of the role of verapamil to the regulation of intracellular drug concentration, without any effect on the intracellular targets of doxorubicin. Recent works showing the inhibition of anticancer drug binding to P-glycoprotein by verapamil agree with this conception of verapamil effect (Cornwell et al., 1986; Safa, 1988) .
Both pharmacological and molecular arguments led us to the conclusion that complementary mechanism(s) other than P-glycoprotein-mediated drug efflux are operating in C6 0.5 cells, and probably also to a lesser extent in C6 0.1 cells, whereas C6 0.001 cells appear as 'pure' P-glycoproteinmediated multidrug resistant cells. Schuurhuis et al. (1989) have shown that a high enough concentration of verapamil (32 ELM) could completely reverse the resistance of colchicineresistant Chinese hamster ovary cells which were 350-fold doxorubicin resistant; the authors show that verapamil was able to shift doxorubicin from cytoplasm to nucleus, which explains a verapamil-induced reduction of doxorubicin incorporation at a given cytotoxicity. With our cells, we never observed such a verapamil-induced reduction of doxorubicin incorporation at IC50 exposure; the elegant demonstration of these authors, that the complete doxorubicin-resistant pattern of their cells was explained by an enhancement of active drug efflux and a change in intracellular doxorubicin distribution, is therefore not valid in our cells.
Several 'multifactorial' doxorubicin-resistant lines have already been obtained. A P-glycoprotein-independent mechanism of resistance to doxorubicin and other natural products has recently been described (Danks et al., 1988) and assigned to alteration of DNA-topoisomerase II; it was called at-MDR by contrast to P-glycoprotein-mediated MDR (P-gp MDR). Other mechanisms of resistance to doxorubicin have been postulated without definitive demonstration; they often involve the role of glutathione-related enzymes and imply an enhanced detoxication of drugs or of products of drug action (Mitchell, 1988; Singh et al., 1989) .
It has not often been considered that several mechanisms could be operating together in the same cell line. Our experiments bring some evidence that P-glycoprotein, although overexpressed in all resistant variants, can explain by itself the resistance of the least resistant C6 line, but cannot be sufficient to account for the resistance phenotype of our most resistant variants. We are now identifying the mechanisms complementary to 'classical' MDR which could explain these complex phenotypes.
